ACT Brief: Bridging Site-Sponsor Data Gaps, Major Study Retraction, and TNBC First-Line Approval

This is the Applied Clinical Trials Brief—your fast track to the latest insights shaping clinical operations and drug development.

• Following DIA 2026, Jonathan Andrus, co-CEO of CRIO, described how central eSource integration can bridge fragmentation between site systems and sponsor oversight. His model combines protocol-driven templates with site-level flexibility, reducing administrative burden while enabling better patient focus.
• Nature Medicine retracted a Phase III lung cancer study after identifying documentation discrepancies, mid-trial protocol changes on ClinicalTrials.gov, and unusual data patterns inconsistent with typical Phase III datasets. The LungTIME-C01 trial claimed dramatic survival benefits from morning immunochemotherapy administration but lacked audit confidence in its integrity.
• The FDA approved Gilead's Trodelvy for first-line metastatic triple-negative breast cancer, both as monotherapy and combined with pembrolizumab. ASCENT-03 showed 38% reduction in disease progression versus chemotherapy, marking the first new backbone therapy for this disease in over two decades.

That's all for today's ACT Brief. Join us next week for more updates shaping clinical operations and drug development. Thanks for listening.